Elvina Almuradova/X
Nov 24, 2024, 18:03
Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer
Elvina Almuradova, Associate Professor at Medicana Health Group, shared a post on X:
“FDA approves Zanidatama for HER2+ biliary tract cancer based on HERIZON-BTC-01 trial results:
- ORR: 52%
- DOR: 14.9 months
- First dual HER2-targeted bispecific antibody for BTC
The confirmatory Phase III trial is ongoing.”
Read more about the FDA approval of Zanidatama on oncodaily.com.
More posts featuring Elvina Almuradova.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 24, 2024, 18:04
Nov 24, 2024, 18:03
Nov 24, 2024, 18:00
Nov 24, 2024, 17:10
Nov 24, 2024, 17:08
Nov 24, 2024, 17:02